Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.37 |
| ▸ | LIG1 | P18858 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16874839 | 0.82 | TLR9 (0.40) | SLC6A2SLC6A4SLC6A3TLR9TLR8 | |
| Hydrochloric Acid SCHEMBL16874598 | 0.81 | TLR9 (0.39) | SLC6A2SLC6A4SLC6A3TLR9TLR8 | |
| SCHEMBL31510742 | 0.79 | KDM1A (0.39) | SLC6A2SLC6A4SLC6A3TLR9TLR8 | |
| SCHEMBL10292141 | 0.79 | HTR3A (0.49) | HTR3ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL2159199 | 0.79 | HTR3A (0.49) | HTR3ASLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL16885912 | 0.78 | MAOA (0.44) | TLR9TLR8TLR7KDM1AHTR2C | |
| SCHEMBL31341890 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TLR9TLR8 | |
| SCHEMBL28592229 | 0.77 | LIG1 (0.44) | HTR3AKDM1ARCOR1LIG1MAOA | |
| SCHEMBL23551723 | 0.76 | ADRB1 (0.40) | TLR9TLR8TLR7 | |
| SCHEMBL31510706 | 0.73 | TLR9 (0.37) | SLC6A2SLC6A4SLC6A3TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| WO-2012078633-A2 | METHODS OF INHIBITING METASTASIS FROM CANCER | PHILADELPHIA HEALTH AND EDUCATION CORPORATION, D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICENE (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | HTR3A 2267/4885SLC6A2 1341/4885SLC6A4 1587/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | HTR3A 1734/4885SLC6A2 3041/4885SLC6A4 2884/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | HTR3A 2267/4885SLC6A2 1341/4885SLC6A4 1587/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | HTR3A 1501/4885SLC6A2 1145/4885SLC6A4 1517/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | HTR3A 2267/4885SLC6A2 1341/4885SLC6A4 1587/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | HTR3A 2267/4885SLC6A2 1341/4885SLC6A4 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.